# Genesis Innovation Group

> Genesis Innovation Group is a VC fund backing Health Care and Medical Device. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Holland, United States
- Total investments: 9
- Last investment: Mar 2025
- Lead investor: 67%
- Fund size: $7.2M
- Last fund: Mar 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/genesis-innovation-group/
- X (Twitter): https://twitter.com/GenesisGroup_MI
- Website: http://genesisinnovationgroup.com/
- Facebook: https://www.facebook.com/GenesisInnovationGroup/

Genesis Innovation Group is a VC fund in Holland focused on Health Care and Medical Device. Genesis is a technology driven firm, focused on the orthopedic space. Rather than focusing on a particular technology, Genesis is driven by the creation of value by identifying and understanding gaps in the orthopedic marketplace that provide opportunities where new technologies can improve the circumstances for all stakeholders in the carestream. With the belief that success depends on partnerships built on transparency and humility, Genesis is built on partnerships between accomplished and sucessful surgeons, commercial entities, and engineers. Genesis is more than an R&D consulting firm. It's strategy most commonly includes a deep engagement (and self financing) which drives partnerships toward shared objectives, creating an ideal win/win relationship.

## Contacts

5 contacts available for Genesis Innovation Group. Shizune tracks 7 team members at Genesis Innovation Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/genesis-innovation-group?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 44% |
| Medical Device | 4 | 44% |
| Biotechnology | 2 | 22% |
| Advanced Materials | 2 | 22% |
| Information Technology | 2 | 22% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 33% |
| Series A | 2 | 22% |
| Series B | 1 | 11% |
| Series C | 1 | 11% |
| Funding Round | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chance W. Leonard | Chief Executive Officer | 0 | https://shizune.co/investors/profile/chance-w-leonard |
| David Blue | Director of VP Sales and Marketing | 0 | https://shizune.co/investors/profile/david-blue |
| Don Running | Vice President,Research & development | 0 | https://shizune.co/investors/profile/don-running |
| Jeff Ondrla | Vice President of Quality, Regulatory & Supply Chain | 0 | https://shizune.co/investors/profile/jeff-ondrla |
| Len Tokish | Vice President of Quality and Regulatory | 0 | https://shizune.co/investors/profile/len-tokish |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| HAPPE Spine | HAPPE Spine is a healthcare company that provides for the optimal mechanical properties of PEEK polymer materials. It also provides improved surface texture inviting boney engagement, interconnected porosity for long term fixation, and the bioactive properties. | $3.4M | Series A | Mar 29, 2025 |  |
| Embody | Embody Inc is a regenerative medicine company that focuses on the development and commercialization of implantable medical devices to address the unmet demands in soft tissue restoration and regeneration. The company specializes in biomaterial design, bio-fabrication, nanotechnology, and medical devices.It was founded in 2015 and headquartered inNorfolk, Virginia. | $10.4M | Series C | Sep 20, 2022 |  |
| Virtual Incision | Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications. | $20M | Series B | Jan 08, 2020 |  |
| Embody | Embody Inc is a regenerative medicine company that focuses on the development and commercialization of implantable medical devices to address the unmet demands in soft tissue restoration and regeneration. The company specializes in biomaterial design, bio-fabrication, nanotechnology, and medical devices.It was founded in 2015 and headquartered inNorfolk, Virginia. | $3.6M |  | Mar 08, 2019 |  |
| Shoulder Innovations | Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leveragesthis technology to create simple surgical instrumentation, which reduces operative time and cost.Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery. | $2.5M | Series A | Oct 22, 2018 |  |
| HAPPE Spine | HAPPE Spine is a healthcare company that provides for the optimal mechanical properties of PEEK polymer materials. It also provides improved surface texture inviting boney engagement, interconnected porosity for long term fixation, and the bioactive properties. |  | Seed | Jul 19, 2018 |  |
| SafKan Health | SafKan Health is transforming ear care with OtoSet® — its viral, FDA-cleared ear cleaning system. Now available at its All Ears Ear Care Studios nationwide. |  | Seed | Jun 01, 2018 |  |
| Shoulder Innovations | Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leveragesthis technology to create simple surgical instrumentation, which reduces operative time and cost.Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery. | $1.6M | Series A | Mar 07, 2017 |  |
| Magnesium Development Company | Magnesim Development Company, LLC (MDC) is a medical device development company delivering devices of a breakthrough resorbable metal alloy technology combining the strength and handling properties of metal with complete absorption for application in sports medicine orthopedics.Why is this important?Existing materials available forsurgical repair marginally meet current surgical demands. Unsolved problems remain (delayed or lack of resorption, loose bodies, cyst formation, mechanical failure, post-operative imaging, etc) in surgical repair of soft tissue injuries (including knee, shoulder, and lower extremities). Occurrence of soft tissue, sports injury related medical events continue to grow as patients remain active longer, and expectations for return to activity increase. With more natural absorption, there remains potential for a bone growth stimulative effect, further enabling the return to activity and lifestyle. | $1M | Seed | Mar 21, 2016 |  |

9 of 9 investments shown.

## Co-investors
- [Wakestream Ventures](https://shizune.co/investors/profile/wakestream-ventures) — VC Fund, 3 deals together
- [cultivate(MD)](https://shizune.co/investors/profile/cultivate-md) — VC Fund, 2 deals together
- [Michigan Angel Fund](https://shizune.co/investors/profile/michigan-angel-fund) — VC Fund, 2 deals together
- [Bluestem Capital](https://shizune.co/investors/profile/bluestem-capital) — VC Fund, 1 deal together
- [Creative Destruction Lab](https://shizune.co/investors/profile/creative-destruction-lab) — VC Fund, 1 deal together
- [J. Hunt Holdings](https://shizune.co/investors/profile/jhh-vc) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Genesis Innovation Group invest in?

Genesis Innovation Group invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Genesis Innovation Group?

Public channels for Genesis Innovation Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Genesis Innovation Group?

The team at Genesis Innovation Group includes Chance W. Leonard (Chief Executive Officer), David Blue (Director of VP Sales and Marketing) and Don Running (Vice President,Research & development), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co